What is Tris Pharma?
Tris Pharma is a privately owned pharmaceutical company specializing in the commercialization of differentiated ADHD medications. The company leverages a novel technology platform for development and licensing partnerships, while also focusing on growing its niche generics business. This dual approach positions Tris Pharma to address specific market needs within the pharmaceutical landscape.
How much funding has Tris Pharma raised?
Tris Pharma has raised a total of $5M across 1 funding round:
Debt
$5M
Debt (2020): $5M with participation from PPP
Key Investors in Tris Pharma
PPP
Public-Private Partnership
What's next for Tris Pharma?
With a major strategic investment and substantial total funding, Tris Pharma is poised for accelerated growth and expansion. The company's focus on its branded ADHD portfolio and niche generics, combined with its technology platform for partnerships, suggests a strategic push towards market penetration and potential new product development. This financing will likely fuel further research, commercialization efforts, and strategic alliances, solidifying its position in the competitive pharmaceutical market.
See full Tris Pharma company page